-
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab
Hogenboom, L., Schoof, L. G., Gelissen, L. M. Y., Mostert, J., van Rooij, L., Hoitsma, E., van Munster, C. E. P., van Eijk, J., Kalkers, N. F., Adriani, K. S., Vennegoor, A., Arts, I. M. P., Mensing, L., Eurelings, M., de Gans, K., Gerlach, O., Hoogervorst, E. L. J., Kloosterziel, M. E., Kragt, J. J. & Portier, R. P. & 14 others, , 1 Jul 2026, In: European Journal of Neurology. 33, 7, e70695.Research output: Contribution to Journal › Article › Academic › peer-review
-
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions
Schoof, L. G., Hogenboom, L., van Kempen, Z. L. E., Killestein, J., van Oosten, B. W. & Strijbis, E. M. M., 1 Apr 2026, In: Multiple Sclerosis Journal - Experimental, Translational and Clinical. 12, 2Research output: Contribution to Journal › Article › Academic › peer-review
-
Author response to letter to the editor
Gelissen, L. M. Y., Hogenboom, L. & van Kempen, Z. L. E., 15 Jan 2026, In: Journal of the Neurological Sciences. 480, 125704.Research output: Contribution to Journal › Comment / Letter to the editor › Academic
- All publications
